Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly’s Zepbound wins weight loss duel with Novo’s Wegovy
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease. Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly, Kenosha County
Eli Lilly’s $3 billion expansion in Kenosha County will mean 750 new jobs
Indianapolis-based Eli Lilly's expansion into Bristol will focus on manufacturing injectable medications, device assembly and packaging for other various medications.
Drug maker Eli Lilly announces $3 billion expansion, 750 new jobs in Kenosha County.
Eli Lilly and Company, an international pharmaceutical company, announced Thursday a $3 billion expansion at a facility it recently acquired in Kenosha County. The company's development plans call for the addition of about 750 jobs at the Town of Bristol location.
Eli Lilly announces $3 billion expansion at manufacturing site in Wisconsin
Eli Lilly and Company has announced a $3 billion expansion to a manufacturing facility in Wisconsin that is set to bring over 700 new jobs to the area. According to a news release, the multinational pharmaceutical company confirmed its plans to extend the scope of its manufacturing facility in Kenosha County which was acquired
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly Invests $3B to Expand Wisconsin Factory to Help Meet Demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments
Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
2d
on MSN
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
2d
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
1d
on MSN
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
21h
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
1d
on MSN
Lilly to Boost Obesity Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Mounjaro
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback